Day: December 10, 2025

FibroBiologics Files Patent Application Covering Novel Fibroblast-Based Chondrocyte Spheroid Platform for Orthopedic and Musculoskeletal Conditions

Written by Customer Service on December 10, 2025. Posted in Public Companies.

Platform Poised to Expand into Joint and Cartilage Repair HOUSTON, Dec. 10, 2025 (GLOBE NEWSWIRE) — FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that it has submitted a new patent application with the U.S. Patent and Trademark Office (USPTO) titled “Spheroids For Cartilage Repair” covering a proprietary fibroblast-derived therapy platform for use in orthopedic and musculoskeletal conditions, including degenerative disc repair, cartilage repair, and joint restoration. The application, if granted, strengthens the protection for the Company’s novel fibroblast technology that...

IQSTEL Announces 2025 Accomplishments and Strategic Priorities for 2026 in New Interview

Written by Customer Service on December 10, 2025. Posted in Public Companies.

2025 Achievements Lay Foundation for Accelerated 2026 Expansion NEW YORK, Dec. 10, 2025 (GLOBE NEWSWIRE) — IQSTEL Inc. (NASDAQ: IQST) (“IQSTEL”), a leading provider of innovative telecommunications and technology solutions, today announced highlights from its 2025 performance in a year‑end executive interview, underscoring achievements that have positioned the company for accelerated growth in 2026. The leadership team detailed how disciplined execution, liability management, and strategic investments in their partners strengthened the company’s foundation while expanding its portfolio of products and services. With organizational alignment and a clear roadmap in place, IQSTEL enters 2026 focused on organic growth, corporate expansion, and delivering enhanced value to clients, partners, and shareholders. The interview...

Veru to Report Fiscal Year 2025 Financial Results on December 17th

Written by Customer Service on December 10, 2025. Posted in Public Companies.

MIAMI, FL, Dec. 10, 2025 (GLOBE NEWSWIRE) — Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced it will host a conference call and audio webcast on Wednesday, December 17, 2025, at 8:00 a.m. ET to discuss its fiscal year 2025 financial results and to provide a business update. The audio webcast will be accessible under the Home page and Investors page of the Company’s website at www.verupharma.com. To join the conference call via telephone, please dial 1-800-341-1602 (domestic) or 1-412-902-6706 (international) and ask to join the Veru Inc. call. An archived version of the audio webcast will be available for replay on the Company’s website for approximately three months. A telephonic replay...

Falco Initiates an Update to its Horne 5 Project’s 2021 Feasibility Study

Written by Customer Service on December 10, 2025. Posted in Public Companies.

MONTREAL, Dec. 10, 2025 (GLOBE NEWSWIRE) — Falco Resources Ltd. (TSX-V:FPC) (“Falco” or the “Corporation”) is pleased to announce that it has initiated an update of the feasibility study for its flagship Horne 5 Project located in Rouyn-Noranda, Québec (the “Horne 5 Project” or the “Project”). Falco anticipates that this study will be completed in the second quarter of 2026 and that it will reflect the considerable potential of the Project considering the significant changes in commodity prices since the release of the feasibility study for the Project in 2021 (the “2021 Feasibility Study”). Having completed the public hearing process with the Office of Public Hearings on the Environment (Québec) last year, the Corporation continues to work toward receiving the necessary ministerial decree authorizing the Project in the coming...

VisionWave Announces Intent to Pursue Multi-Patent Portfolio for Argus Space-Enabled Counter-UAS System

Written by Customer Service on December 10, 2025. Posted in Public Companies.

WEST HOLLYWOOD, Calif., Dec. 10, 2025 (GLOBE NEWSWIRE) — VisionWave Holdings, Inc. (Nasdaq: VWAV) (“VisionWave”) or (the “Company”) today announced that it has initiated the patent-application process for a planned series of patents with the goal of covering key technologies underlying Argus, the Company’s space-enabled, AI-driven counter-unmanned aircraft system (C-UAS) platform. This step follows the Company’s prior public statement that it planned to pursue patent protection for the Argus platform. VisionWave has now engaged its intellectual-property counsel and begun preparing an initial set of provisional patent applications focused on Argus’s core system architecture and enabling technologies. These include, among other elements, the SkyWeave™️ high-frequency (HF) AI-driven communications backbone; space- and...

Moleculin Announces Exercise of Warrants for $6.8 Million Gross Proceeds

Written by Customer Service on December 10, 2025. Posted in Public Companies.

HOUSTON, Dec. 10, 2025 (GLOBE NEWSWIRE) — Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced it has entered into agreements with certain holders of its existing warrants for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 727,969 shares of common stock of the Company originally issued in February 2025 at an exercise price of $6.63 per share and 316,360 shares of common stock of the Company originally issued in August 2025 at an exercise price of $6.3219 per share. The shares of common stock issuable upon exercise of the outstanding warrants are registered pursuant to effective registration statements on Form S-1 (File No. 333-286276)...

TransGlobal Assets, Inc. (OTC: TMSH) Signs Letter of Intent to Acquire Majority Control of M Love Vintage Holdings, Inc., a High-Growth Denim & Heritage Apparel Brand

Written by Customer Service on December 10, 2025. Posted in Mergers And Acquisitions.

PORTSMOUTH, N.H., Dec. 10, 2025 (GLOBE NEWSWIRE) — TransGlobal Assets, Inc. (OTC: TMSH), a Wyoming corporation focused on innovation at the intersection of AI, emotional intelligence, and fintech, is pleased to announce that it has executed a Letter of Intent (“LOI”) to acquire majority control of M Love Vintage Holdings, Inc. (“M Love”), an upscale boutique brand specializing in rare American workwear and curated vintage apparel.Under the LOI, TMSH intends to acquire all issued and outstanding shares of M Love from Green Rain Energy Holdings Inc. (OTC: GREH). Upon closing, M Love will operate as a wholly owned subsidiary of TMSH. A Strategic Acquisition Aligned With Next-Generation Consumer & Technology Trends The LOI highlights TMSH’s long-term strategy of merging high-value, culturally relevant consumer brands with technology-driven...

NuCana Presents Latest Data Demonstrating Clinical Activity and Favorable Safety for NUC-7738 in Patients with PD-1-Resistant Melanoma

Written by Customer Service on December 10, 2025. Posted in Public Companies.

Data Presented at ESMO IO 2025 include Partial Responses, Durable Disease Control, and No New Safety Signals, Reinforcing Earlier Findings EDINBURGH, United Kingdom, Dec. 10, 2025 (GLOBE NEWSWIRE) — NuCana plc (NASDAQ: NCNA) (“NuCana” or the “Company”) presented the latest clinical data at the annual European Society for Medical Oncology (“ESMO”) Immuno-Oncology Congress, December 10-12, 2025, in London. The data from patients with PD-1 inhibitor-resistant metastatic melanoma treated with NUC-7738 in combination with pembrolizumab continue to demonstrate clinical activity and a favorable safety profile. All patients had progressive disease prior to starting treatment. Clinical activity includes two partial responses (one confirmed) and seven cases of stable disease, notably including one ongoing stable disease converting to a...

ScanTech AI Systems Strengthens Strategic Leadership to Accelerate Growth and Global Commercial Execution with Appointment of Michael D.P. Cavanaugh to Board of Directors

Written by Customer Service on December 10, 2025. Posted in Public Companies.

Michael D.P. CavanaughMichael D.P. CavanaughMichael D.P. Cavanaugh Atlanta, GA, Dec. 10, 2025 (GLOBE NEWSWIRE) — ScanTech AI Systems Inc. (Nasdaq: STAI) (“ScanTech AI” or the “Company”), a developer of advanced AI-powered security screening and imaging technologies, today announced that Michael D.P. Cavanaugh has been appointed to its Board of Directors, enhancing the Company’s strategic, operational, and governance capabilities as it advances its commercialization and global expansion initiatives. The Board of Directors has determined that Mr. Cavanaugh is an “independent director” under the applicable rules of The Nasdaq Stock Market LLC and the Securities and Exchange Commission and has appointed him to serve on the Audit Committee and the Compensation Committee of the Board. Mr. Cavanaugh brings more than two decades...

PetMeds Announces Holiday Collection: Wellness-Focused Gifts for Pets and the People Who Love Them

Written by Customer Service on December 10, 2025. Posted in Public Companies.

DELRAY BEACH, Fla., Dec. 10, 2025 (GLOBE NEWSWIRE) — PetMed Express, Inc., d/b/a PetMeds and parent company of PetCareRx, (Nasdaq: PETS) (the “Company”), today unveiled its new Holiday Collection, a curated selection of health, wellness, and lifestyle products designed for pet parents who want to give purposeful, practical gifts this season. Unlike traditional pet gifts such as toys or beds, PetMeds’ giftable assortment focuses on products that improve pets’ everyday health, comfort, safety, and happiness, making them ideal for the pet owner who has everything. “With more pet parents treating their furry friends like true members of the family, holiday gifting has shifted toward smart, wellness-oriented products,” said Leslie Campbell, CEO at PetMeds. “This collection offers gifts that actually make a difference, offering everything...

Day: December 10, 2025

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals